CG Oncology, Inc. (CGON)
NASDAQ:CGON
Want to see CGON full AI Analyst Report?
CGON Stock Chart & Stats
$73.43
-$0.55(-1.77%)
At close: 4:00 PM EST
$73.43
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$23.65 - $75.50
Previous Close$30.46
Volume740.02K
Average Volume (3M)931.59K
Market Cap
$5.49B
Enterprise Value$5.47B
Total Cash (Recent Filing)$1.08B
Total Debt (Recent Filing)$7.58M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 07, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding88,202,480
10 Day Avg. Volume1,000,313
30 Day Avg. Volume931,592
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.08K
Enterprise Value/Gross Profit-2.30K
Enterprise Value/Ebitda-27.62
Forecast
1Y Price Target
$92.50Price Target Upside25.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.72
Revenue Forecast (FY)$11.76M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely strong equity relative to debt gives the company durable financial flexibility to fund multi-year R&D, pivotal trials and initial commercialization efforts without immediate refinancing. This reduces solvency risk and supports sustained investment in core programs.
Experienced Financial LeadershipInstalling a seasoned biotech CFO with milestone-linked equity aligns management incentives to commercialization and cash‑flow objectives. Improved financial stewardship should strengthen forecasting, capital strategy and execution as the company approaches revenue and cash‑generation inflection points.
Improving Top-line MomentumSustained revenue growth off a clinical-stage base signals early commercial or trial revenue traction and validates aspects of the go-to-market strategy. Continued top-line expansion, even from a small base, helps narrow the gap versus fixed costs and supports longer‑term margin improvement.
Bears Say
High And Rising Cash BurnPersistent and increasing cash outflows create a structural funding requirement that will likely force additional financings or dilution absent rapid revenue ramp. High burn reduces runway, constrains optionality and increases execution risk during the commercialization transition.
Large, Widening Losses And Negative Gross ProfitSubstantial negative gross profit and widening operating losses indicate the cost base is structurally ahead of revenues. Until scale or pricing power is achieved, margin recovery will be difficult, pressuring returns and making durable profitability contingent on successful commercialization or cost re‑engineering.
Senior Commercial Leadership TurnoverDeparture of a senior commercial leader and an ongoing CCO search during a commercialization phase introduces execution risk. Consolidation of roles under the CEO may preserve continuity short term but could delay commercial planning, partner engagement and launch readiness.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $23.65 and its highest was $75.50 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $5.49B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 65 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on May 08, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.556 by -$0.154.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.66.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 88,202,480 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.556. Following the earnings report the stock price went up 0.636%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.50 (25.97% Upside)
$92.50 (25.97% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
131.18%
12-Months-Change
Fundamentals
Return on Equity
-23.33%
Trailing 12-Months
Asset Growth
55.90%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CGON Stock 12 Month Forecast
Average Price Target
$92.50
▲(25.97% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
9.93% Insiders
24.93% Mutual Funds
11.43% Other Institutional Investors
39.91% Public Companies and
Individual Investors